Cargando…

Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome

Isoflavones are polyphenols primarily contained in soybean. As phytoestrogens, isoflavones exert beneficial effects on various chronic diseases. Metabolic syndrome increases the risk of death due to arteriosclerosis in individuals with various pathological conditions, including obesity, hypertension...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamagata, Kazuo, Yamori, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512040/
https://www.ncbi.nlm.nih.gov/pubmed/34641407
http://dx.doi.org/10.3390/molecules26195863
_version_ 1784582894504640512
author Yamagata, Kazuo
Yamori, Yukio
author_facet Yamagata, Kazuo
Yamori, Yukio
author_sort Yamagata, Kazuo
collection PubMed
description Isoflavones are polyphenols primarily contained in soybean. As phytoestrogens, isoflavones exert beneficial effects on various chronic diseases. Metabolic syndrome increases the risk of death due to arteriosclerosis in individuals with various pathological conditions, including obesity, hypertension, hyperglycemia, and dyslipidemia. Although the health benefits of soybean-derived isoflavones are widely known, their beneficial effects on the pathogenesis of metabolic syndrome are incompletely understood. This review aims to describe the association between soybean-derived isoflavone intake and the risk of metabolic syndrome development. We reviewed studies on soy isoflavones, particularly daidzein and genistein, and metabolic syndrome, using PubMed, ScienceDirect, and Web of Science. We describe the pathological characteristics of metabolic syndrome, including those contributing to multiple pathological conditions. Furthermore, we summarize the effects of soybean-derived daidzein and genistein on metabolic syndrome reported in human epidemiological studies and experiments using in vitro and in vivo models. In particular, we emphasize the role of soy isoflavones in metabolic syndrome-induced cardiovascular diseases. In conclusion, this review focuses on the potential of soy isoflavones to prevent metabolic syndrome by influencing the onset of hypertension, hyperglycemia, dyslipidemia, and arteriosclerosis and discusses the anti-inflammatory effects of isoflavones.
format Online
Article
Text
id pubmed-8512040
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85120402021-10-14 Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome Yamagata, Kazuo Yamori, Yukio Molecules Review Isoflavones are polyphenols primarily contained in soybean. As phytoestrogens, isoflavones exert beneficial effects on various chronic diseases. Metabolic syndrome increases the risk of death due to arteriosclerosis in individuals with various pathological conditions, including obesity, hypertension, hyperglycemia, and dyslipidemia. Although the health benefits of soybean-derived isoflavones are widely known, their beneficial effects on the pathogenesis of metabolic syndrome are incompletely understood. This review aims to describe the association between soybean-derived isoflavone intake and the risk of metabolic syndrome development. We reviewed studies on soy isoflavones, particularly daidzein and genistein, and metabolic syndrome, using PubMed, ScienceDirect, and Web of Science. We describe the pathological characteristics of metabolic syndrome, including those contributing to multiple pathological conditions. Furthermore, we summarize the effects of soybean-derived daidzein and genistein on metabolic syndrome reported in human epidemiological studies and experiments using in vitro and in vivo models. In particular, we emphasize the role of soy isoflavones in metabolic syndrome-induced cardiovascular diseases. In conclusion, this review focuses on the potential of soy isoflavones to prevent metabolic syndrome by influencing the onset of hypertension, hyperglycemia, dyslipidemia, and arteriosclerosis and discusses the anti-inflammatory effects of isoflavones. MDPI 2021-09-27 /pmc/articles/PMC8512040/ /pubmed/34641407 http://dx.doi.org/10.3390/molecules26195863 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Yamagata, Kazuo
Yamori, Yukio
Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome
title Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome
title_full Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome
title_fullStr Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome
title_full_unstemmed Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome
title_short Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome
title_sort potential effects of soy isoflavones on the prevention of metabolic syndrome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512040/
https://www.ncbi.nlm.nih.gov/pubmed/34641407
http://dx.doi.org/10.3390/molecules26195863
work_keys_str_mv AT yamagatakazuo potentialeffectsofsoyisoflavonesonthepreventionofmetabolicsyndrome
AT yamoriyukio potentialeffectsofsoyisoflavonesonthepreventionofmetabolicsyndrome